SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (15845)2/25/1998 12:06:00 PM
From: Andreas Helke  Read Replies (2) | Respond to of 32384
 
I suspect that with Targretin there is a factor that might make things a lot more complicated and difficult. Ligand intends to charge very high prices for Targretin as cancer treatment. I don't think that a type II diabetes patient is ready to pay the price that a cancer patient will gladly pay. If there will be a price difference and if the dosing range is comparable the cheaper diabetes treatment might be used off label to treat cancer. Or it might be necessary to lower the prices for Targretin when the diabetes indication gets approved in a few years.
Does anybody know what doses are used for the various indications?

Andreas



To: Peter Singleton who wrote (15845)2/25/1998 12:13:00 PM
From: David L. Hachey  Read Replies (1) | Respond to of 32384
 
Peter;

This is one scenario for multiple marketing. The active ingredient is the same, but the formulation is different. Another possibility would be dispensing as tablets for diabetes and as i.v. injectable for cancer chemotherapy. Not too many drugs are marketed for multiple indications, but the retinoids are in an unusual product category.

...Dave


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News